Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Launches $100M Share Repurchase Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Illumina announced today that its board of directors has authorized a $100 million share repurchase program.

The firm may acquire on a discretionary basis up to $100 million worth of its outstanding common shares on the open market or through privately negotiated transactions. Its previous $100 million share repurchase program, which was authorized in July 2010, was completed this week, the firm said.

"We believe that the repurchase of our common stock represents an effective use of our capital and underscores our commitment to maximize value for our shareholders, " Illumina CFO and GM of Life Sciences Christian Henry said in a statement. "Since 2008, we have bought over 12 million shares of our common stock through prior authorizations, returning nearly $450 million to shareholders."

Last week, Illumina reported a 36 percent increase in its second quarter sales year over year. It finished the quarter with $261.1 million in cash and cash equivalents and $972.8 million in short-term investments.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.